Insider Selling: Neuronetics Inc (STIM) Insider Sells 3,685 Shares of Stock

Share on StockTwits

Neuronetics Inc (NASDAQ:STIM) insider Daniel Guthrie sold 3,685 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $14.53, for a total transaction of $53,543.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of NASDAQ:STIM opened at $13.09 on Friday. Neuronetics Inc has a 52 week low of $13.26 and a 52 week high of $39.39. The company has a market capitalization of $239.65 million and a price-to-earnings ratio of -4.87. The company has a current ratio of 8.94, a quick ratio of 8.74 and a debt-to-equity ratio of 0.52.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.05). Neuronetics had a negative net margin of 47.21% and a negative return on equity of 1,385.60%. The firm had revenue of $12.73 million during the quarter, compared to analyst estimates of $12.72 million. Sell-side analysts predict that Neuronetics Inc will post -1.64 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Neuronetics by 50.3% during the first quarter. BlackRock Inc. now owns 920,747 shares of the company’s stock worth $14,040,000 after purchasing an additional 308,324 shares during the last quarter. Lord Abbett & CO. LLC raised its holdings in Neuronetics by 2.5% during the 4th quarter. Lord Abbett & CO. LLC now owns 428,007 shares of the company’s stock worth $8,282,000 after purchasing an additional 10,414 shares during the last quarter. Wasatch Advisors Inc. raised its holdings in Neuronetics by 23.5% during the 1st quarter. Wasatch Advisors Inc. now owns 313,954 shares of the company’s stock worth $4,788,000 after purchasing an additional 59,740 shares during the last quarter. Pier Capital LLC raised its holdings in Neuronetics by 12.8% during the 1st quarter. Pier Capital LLC now owns 310,375 shares of the company’s stock worth $4,733,000 after purchasing an additional 35,339 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Neuronetics by 1,510.2% during the 3rd quarter. Vanguard Group Inc. now owns 241,533 shares of the company’s stock worth $7,744,000 after purchasing an additional 226,533 shares during the last quarter. Institutional investors and hedge funds own 72.57% of the company’s stock.

Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday, April 13th. Piper Jaffray Companies dropped their price target on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 5th. Finally, BTIG Research restated a “buy” rating and issued a $25.00 price target on shares of Neuronetics in a research note on Wednesday, March 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $31.60.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Neuronetics Inc (STIM) Insider Sells 3,685 Shares of Stock” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/4353205/insider-selling-neuronetics-inc-stim-insider-sells-3685-shares-of-stock.html.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Read More: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Welbilt  Lifted to “Hold” at ValuEngine
Welbilt Lifted to “Hold” at ValuEngine
Wintrust Financial  Downgraded to Strong Sell at ValuEngine
Wintrust Financial Downgraded to Strong Sell at ValuEngine
Vectura Group  Upgraded to Hold at ValuEngine
Vectura Group Upgraded to Hold at ValuEngine
American Airlines Group  Stock Rating Upgraded by BidaskClub
American Airlines Group Stock Rating Upgraded by BidaskClub
TowneBank  Downgraded by ValuEngine
TowneBank Downgraded by ValuEngine
Tonix Pharmaceuticals  Stock Rating Lowered by ValuEngine
Tonix Pharmaceuticals Stock Rating Lowered by ValuEngine


© 2006-2019 Ticker Report